CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-11-18 | RIOS MIGUEL DE LOS VP - Research | Grant or award · Common Stock Option (right to buy) | +34,020 | 147,102 | ||
| 2014-11-18 | GRAZIANO JAMES JOSEPH Chief Technology Officer | Grant or award · Common Stock Option (right to buy) | +28,140 | 28,140 | ||
| 2014-11-18 | BROOKS JOEL Chief Financial Officer | Grant or award · Common Stock Option (right to buy) | +28,140 | 47,300 | ||
| 2014-11-18 | BRACA JOHN N Director | Grant or award · Common Stock Option (right to buy) | +31,698 | 72,644 | ||
| 2014-11-18 | BRACA JOHN N Director | Grant or award · Common Stock Option (right to buy) | +5,270 | $0.42 | $2K | 77,914 |
| 2014-06-25 | MARTELL RON Chief Executive Officer | Grant or award · Employee Stock Option | +400,000 | 400,000 | ||
| 2014-06-13 | FROST PHILLIP MD ET AL Director | Returned to the company · Series A Warrants | −333,333 | 0 | ||
| 2014-06-13 | FROST PHILLIP MD ET AL Director | Returned to the company · Series FA Warrants | −211,626 | 0 | ||
| 2014-06-13 | FROST PHILLIP MD ET AL Director | Grant or award · Series A Warrants | +333,333 | 333,333 | ||
| 2014-06-13 | FROST PHILLIP MD ET AL Director | Grant or award · Series FA Warrants | +211,626 | 211,626 | ||
| 2014-06-13 | SMIDER VAUGHN See Remarks | Returned to the company · Series FA Warrants | −242,563 | 7,411 | ||
| 2014-06-13 | SMIDER VAUGHN See Remarks | Returned to the company · Series FA Warrants | −7,411 | 0 | ||
| 2014-06-13 | SMIDER VAUGHN See Remarks | Grant or award · Series FA Warrants | +242,563 | 242,563 | ||
| 2014-06-13 | SMIDER VAUGHN See Remarks | Grant or award · Series FA Warrants | +7,411 | 249,974 | ||
| 2014-06-13 | GRAZIANO JAMES JOSEPH Chief Technology Officer | Returned to the company · Series FA Warrants | −24,641 | 0 | ||
| 2014-06-13 | GRAZIANO JAMES JOSEPH Chief Technology Officer | Grant or award · Series FA Warrants | +24,641 | 24,641 | ||
| 2014-05-16 | SMIDER VAUGHN Chief Scientific Officer | Grant or award | +1,027,574 | 1,058,970 | ||
| 2014-05-16 | SMIDER VAUGHN Chief Scientific Officer | Grant or award | +31,396 | 1,058,970 | ||
| 2014-05-16 | SMIDER VAUGHN Chief Scientific Officer | Grant or award · Warrants | +242,563 | 242,563 | ||
| 2014-05-16 | SMIDER VAUGHN Chief Scientific Officer | Grant or award · Warrants | +7,936 | 7,936 |
Page 19 of 20 · 388 trades